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Long-term effectiveness and 
safety of varenicline and nicotine 
replacement therapy in people with 
neurodevelopmental disorders: A 
prospective cohort study
Taha itani1,2, Dheeraj Rai3,4,5, Tim Jones6, Gemma M. J. taylor7, Kyla H. thomas8, 
Richard M. Martin  1,5,8, Marcus R. Munafò  1,2, Neil M. Davies  1,8 & Amy E. taylor5,8*
This study aimed to determine the effectiveness and safety of varenicline versus NRT for smoking 
cessation in people with neurodevelopmental disorders, compared to those without, at up to four 
years after exposure. We analysed electronic medical records from the Clinical Practice Research 
Datalink using three different statistical approaches: multivariable logistic regression, propensity 
score matching (PSM), and instrumental variable analysis. Exposure was prescription of varenicline 
versus NRT and the primary outcome was smoking cessation at 2-years. We included 235,314 people 
aged 18 and above with eligible smoking cessation prescriptions in the effectiveness analysis. Smokers 
with neurodevelopmental disorders were 48% less likely (95% confidence interval: 42%, 54%) to be 
prescribed varenicline than NRT, compared to smokers without neurodevelopmental disorders. At 
2-year follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38% more 
likely to quit smoking (95% confidence interval: 6%, 78%). Similar results were obtained using PSM 
and instrumental variable analyses. There was little evidence showing that varenicline increased the 
likelihood of mental health related adverse events in people with neurodevelopmental disorders. 
Varenicline is less likely to be prescribed to people with neurodevelopmental disorders despite results 
suggesting it is more effective than NRT and little evidence of increased likelihood of mental health 
related adverse events.
Intellectual disability, autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) 
are neurodevelopmental disorders with a cumulative prevalence of at least 5% in the general population. There is 
increasing evidence that people with neurodevelopmental disorders experience health inequalities and up to 16 
years of premature mortality as compared to those without these conditions1. For instance, those with intellectual 
disabilities are more likely to have worse physical and mental health and receive poorer quality health care when 
compared to the general population in the United States2, Canada3, and the UK4,5.
Smoking prevalence amongst people with ADHD is higher than that in the general population6, individuals 
with ADHD start smoking at an earlier age6,7 and find it more difficult to quit smoking compared to the gen-
eral population8. Studies conducted in developed nations estimate that 36 to 42% of adults with ADHD smoke 
compared to 26% in those without ADHD6,9. These prevalence estimates were based on old data (prior to 1997) 
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and may not reflect the current trends. Conversely, there is evidence to suggest that smoking prevalence is low 
amongst people with ASD. A Swedish study of 95 adults with ASD found that 13% were smokers10 compared to 
19% in the general population11. Variations in smoking prevalence might be due to various reasons including 
different neurobiological underpinnings (e.g. the role of dopaminergic pathways in ADHD), phenotypic differ-
ences (e.g. impulsivity and high-risk behaviours in ADHD vs typically more rule abiding behaviours in autism) 
or access to smoking due to disorder severity, as individuals with mild to moderate intellectual disabilities have 
higher smoking rates than those with more severe intellectual disabilities12. However, there is limited evidence on 
smoking rates amongst people with neurodevelopmental disorders in the UK: amongst 435 adults with learning 
disabilities in one large urban area of central UK a smoking prevalence of 6.2% was observed (lower than the 
general population)13.
There is a lack of evidence about the effectiveness of smoking cessation medications amongst smokers with 
neurodevelopmental disorders. Varenicline, a nicotinic receptor partial agonist, is a more effective smoking cessa-
tion agent than placebo, NRT and bupropion in randomised controlled trials14,15 and in the general population16. 
However, no studies have been conducted to assess the effectiveness of varenicline on smoking cessation amongst 
people with neurodevelopmental disorders.
Since its launch, spontaneous reporting systems have highlighted concerns about the safety of varenicline, 
particularly in relation to mental health17. These concerns prompted the Medicines and Healthcare Products 
Regulatory Agency (MHRA) to issue safety warnings about varenicline in the UK18 and the U.S. Food and Drug 
Administration (FDA) to require the addition of a black box warning to the labelling of varenicline (removed in 
2016)19. Empirical studies indicate no clear evidence of an increased risk of neuropsychiatric side effects includ-
ing suicidal behaviour in the general and psychiatric populations associated with varenicline (versus NRT or 
placebo)17,20–22. However, these safety issues have not been investigated in people with neurodevelopmental 
disorders.
While considering that people with neurodevelopmental disorders may suffer from health inequalities and 
that there is a scarcity of information about smoking prevalence and smoking cessation treatment, shedding more 
light on these potentially avoidable issues could foster health equality in this patient group. Hence, we aimed to: 
(1) describe smoking prevalence and rates of prescribing of smoking cessation medication in people with neu-
rodevelopmental disorders in primary care from 2004 to 2015, as compared to those without these disorders, 
and (2) determine the effectiveness and safety of varenicline versus NRT for smoking cessation in people with 
neurodevelopmental disorders, compared to those without these disorders, at 3, 6, 9 months and 1, 2, 4 years after 
exposure.
Results
Population characteristics. Between September 1st, 2006 and January 25th, 2016, there were 235,314 people 
with eligible prescriptions for smoking cessation medications (Please see eFigure 1 in the online supplemental 
data displaying the number of patients excluded and reasons for exclusion.). Amongst those with neurodevelop-
mental disorders (N = 2,346), 1,882 and 464 smokers were prescribed NRT and varenicline, respectively. People 
with neurodevelopmental disorders were on average about 10 years younger, more likely to be males, more likely 
to have alcohol and drug misuse, and were diagnosed with more lifetime mental health disorders than those 
without neurodevelopmental disorders (Table 1).
Prevalence of smoking and of prescribing of smoking cessation medication over time. The 
age and sex standardised prevalence of smoking amongst people with neurodevelopmental disorders was 23.5% 
in 2004, rising to 25.7% in 2010 and decreasing to 22.9% by 2015 (Fig. 1). People with ADHD had the highest 
standardised smoking prevalence, ranging between 34.7% and 37.7% in the study period while people with ASD 
had the lowest standardised smoking prevalence, ranging between 14.9% and 15.7% in the study period. The age 
and sex standardised smoking prevalence amongst people with intellectual disabilities ranged from 21.8% in 2004 
to 20.1% in 2015 (eFigure 2). Amongst those with no neurodevelopmental disorders, smoking rates decreased 
steadily from 28.1% in 2004 to 20.6% in 2015 (Fig. 1).
Standardised NRT prescribing rates fell from 7% to 2–3% between 2007 and 2015 in smokers with and without 
neurodevelopmental disorders. Varenicline prescribing increased between 2007 and 2011 and then fell between 
2011 and 2015 in smokers with and without neurodevelopmental disorders. From 2007 to 2015, NRT prescrib-
ing was higher amongst smokers with neurodevelopmental disorders, while varenicline prescribing was higher 
amongst smokers without neurodevelopmental disorders (Fig. 2).
The effectiveness of varenicline versus NRT for smoking cessation. Smokers with neurodevel-
opmental disorders were 48% (95% confidence interval: 42% to 54%) less likely to be prescribed varenicline 
than NRT, compared to smokers without neurodevelopmental disorders (eTable 3). Amongst smokers with and 
without neurodevelopmental disorder, varenicline was associated with higher quit rates than NRT at all follow-up 
time points (Fig. 3, Table 2 and eTable 4, for partially adjusted models see eTable 5).
After adjusting for all covariates, smokers with no neurodevelopmental disorder prescribed varenicline were 
25% (95% confidence interval: 22% to 27%) more likely to abstain from smoking after two years of follow-up. At 
2-years follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38% (95% confidence 
interval: 6% to 78%) more likely to quit smoking in the fully-adjusted model. Estimates were similar across the 
time points for the group with neurodevelopmental disorders but were imprecise due to smaller sample size 
(Table 2).
The overall trend in the propensity score matched models was consistent with the estimates produced by the 
multivariable logistic regression models (eTable 6). The instrumental variable models indicated that smokers with 
and without any neurodevelopmental disorder were more likely to quit smoking after 2-years when prescribed 
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varenicline vs NRT; the risk difference per 100 people treated (this corresponds to the number of people out of 
100 who would be expected to quit smoking when prescribed varenicline vs. NRT) was 11.98 (0.29 to 23.67) and 
5.31 (3.67 to 6.95), respectively (eTable 7).
Safety of varenicline versus NRT. Amongst patients with neurodevelopmental disorders, there were 
seven cases of death by suicide in those who received NRT and no cases in the varenicline group.
There was little evidence that varenicline increased the likelihood of any of the mental health related adverse 
events (eTables 8–11).
Characteristic
Any neurodevelopmental disorder
(N = 2,346)
No neurodevelopmental disorder
(N = 232,968)
NRT (N = 1,882) Varenicline (N = 464) Total NRT (N = 157,854)
Varenicline 
(N = 75,114) Total
Age at time of first prescriptiona 35.5 (14.4) 34.1 (13.2) 35.3 (14.2) 46.4 (15.2) 44.5 (13.2) 45.8 (14.8)
Sex (male) 1,194 (63.4%) 287 (61.9%) 1,481 (63.1%) 72,666 (46.0%) 37,408 (49.8%) 110,074 (47.3%)
Multiple deprivation score (IMD)b† 4 4 4 3 3 3
Number of GP visits 1-year prior to 
first prescriptiona 9.4 (8.9) 7.8 (9.7) 9.1 (9.1) 7.9 (7.4) 6.3 (6.1) 7.4 (7.0)
BMIa† 27.1 (6.7) 26.2 (6.2) 26.9 (6.6) 26.4 (5.7) 26.5 (5.4) 26.5 (5.6)
Year of first prescriptionb 2010 2011 2010 2009 2010 2009
Days of historya 2,733.3 (1871.0) 3,011.7 (2135.1) 2,788.4 (1928.8) 3,058.1 (1908.1) 3,165.8 (1985.4) 3,092.8 (1934.0)
Comorbidity ever (Charlson Index) 727 (38.6%) 185 (39.9%) 912 (38.9%) 59,116 (37.5%) 23,860 (31.8%) 82,976 (35.6%)
Alcohol misuse ever 197 (10.5%) 54 (11.6%) 251 (10.7%) 13,797 (8.7%) 4,716 (6.3%) 18,513 (8.0%)
Drug misuse ever 109 (5.8%) 24 (5.2%) 133 (5.7%) 4,866 (3.1%) 1,432 (1.9%) 6,298 (2.7%)
Self-harm ever 415 (22.1%) 79 (17.0%) 494 (21.1%) 16,884 (10.7%) 6,582 (8.8%) 23,466 (10.1%)
Ever anxiety and stress related 
disorders 626 (33.3%) 125 (26.9%) 751 (32.0%) 43,906 (27.8%) 17,268 (23.0%) 61,174 (26.3%)
Other behavioural/neurologic 
disorder ever 346 (18.4%) 66 (14.2%) 412 (17.6%) 7,322 (4.6%) 2,529 (3.4%) 9,851 (4.2%)
Ever depression 851 (45.2%) 187 (40.3%) 1,038 (44.3%) 64,709 (41.0%) 25,936 (34.5%) 90,645 (38.9%)
Ever schizophrenia and non-affective 
psychoses 233 (12.4%) 10 (2.2%) 243 (10.4%) 4,030 (2.6%) 431 (0.6%) 4,461 (1.9%)
Ever antidepressants 1,049 (55.7%) 214 (46.1%) 1,263 (53.8%) 78.808 (50.0%) 32,044 (42.7%) 110,852 (47.6%)
Ever antipsychotics 632 (33.6%) 83 (17.9%) 715 (30.5%) 28,515 (18.1%) 9,722 (12.9%) 38,237 (16.4%)
Ever hypnotics/anxiolytics 821 (43.6%) 169 (36.4%) 990 (42.2%) 59,509 (37.7%) 24,985 (33.3%) 84,494 (36.3%)
Ever mood stabilisers 278 (14.8%) 21 (4.5%) 299 (12.8%) 7,365 (4.7%) 1,783 (2.4%) 9,148 (3.9%)
Table 1. Baseline characteristics of patients with or without neurodevelopmental disorders by exposure group, 
N (%). aData presented are mean and standard deviation. bData presented are median. †Missing data: BMI data 
was missing for 14.1% (N = 33,059); IMD data was missing for 43.6% (N = 102,657).
Figure 1. Age and sex standardised percentage (%) of primary care patients with an electronic medical record 
indicating smoking, from 2004 to 2015, in people with or without neurodevelopmental disorders.
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Discussion
Principal findings. To our knowledge, this is the largest study to estimate smoking prevalence amongst 
patients with neurodevelopmental disorders using nationally-representative primary care data and the first to 
assess the effectiveness and safety of varenicline for smoking cessation in this patient group. Our findings indicate 
that smoking prevalence is higher in people with neurodevelopmental disorders (with the exception of patients 
with ASD) than people without these disorders. These individuals are less likely to be prescribed varenicline than 
NRT. However, there was little evidence that the effectiveness of varenicline over NRT is different in this group 
compared to the general population. The results were comparable across the three analytical methods, although 
instrumental variable estimates were imprecise. Furthermore, our analysis of safety outcomes in patients with 
neurodevelopmental disorders found little evidence that varenicline was associated with increased likelihood of 
suicide, self-harm, depression or anxiety. These results were similar across all three analytical methods, albeit with 
limited power to produce precise estimates on varenicline safety.
Strengths and limitations. The main strengths of this study include the use of a representative 
population-based primary care data and triangulating three different analytical methods23 to address con-
founding24. The CPRD is representative of the UK primary care population25, thus our results are likely to be 
Figure 2. Age and sex standardised prescription prevalence of varenicline or NRT in primary care, from 2007 
to 2015, in smokers with any neurodevelopmental disorder, compared to smokers with no neurodevelopmental 
disorder.
Figure 3. Percentage (%) of patients with an electronic medical record indicating smoking cessation at 2-years 
follow-up, by exposure, and neurodevelopmental disorder.
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generalizable to the UK and similar countries. The large sample size allowed us to investigate smoking preva-
lence and cessation in patients with relatively rare neurodevelopmental disorders. Additionally, we used multiple 
imputation to handle missing data on BMI and IMD26 to reduce selection-bias. The consistent results across our 
different statistical modeling techniques suggest that these are less likely to be driven by residual confounding.
A limitation is that we had no information on compliance with taking prescribed smoking cessation medi-
cations as intended. Therefore, the efficacy of varenicline might be underestimated if smokers were less likely to 
adhere to their treatment regimen. Our results might not be generalizable to all people with intellectual disabilities 
since it is considered that the ‘hidden majority’27 of those with mild forms of the disorder tend to have less access 
to screening interventions and might be underdiagnosed in the CPRD. Moreover, smoking records may not 
reflect the up-to-date smoking status which might over- or underestimate the smoking prevalence. Selection bias 
could be a concern since the CPRD database only includes patients who seek primary care services. Additionally, 
data on other important confounders such as parent and peer relations are not captured by the CPRD. Finally, our 
study lacked statistical power to detect small associations between the exposure and the outcome.
Comparison with other studies. There is a lack of population-based studies estimating the smoking prev-
alence in people with neurodevelopmental disorders. We observed a higher smoking prevalence 37.9% (95% CI: 
36.3% to 39.5%) amongst ADHD patients in 2010 than previously reported in the THIN database 27.2% (95% 
CI: 21.0% to 33.3%) in 2009–201028. This may be due to the difference in denominators (i.e., people with missing 
smoking records were excluded from the denominator). We observed higher smoking rates in people with neu-
rodevelopmental disorders as compared to those without. This was consistent with a study in people with and 
without longstanding mental health disorders29. Meanwhile, our data indicate a steady decline of smoking rates 
in people with no neurodevelopmental disorders during the study period which is concordant with smoking 
estimates in the UK’s general population30.
This study indicates a declining trend in NRT prescriptions for smokers with and without developmental dis-
orders. This decline was mirrored in a study that used the THIN data31. Regarding varenicline, our data show an 
initial increase in its prescriptions to smokers in both groups between 2008 and 2011. After varenicline entered 
the drug market in the UK in late 2006, it became the second most prescribed drug for smoking cessation in the 
UK31. From 2007 to 2015, varenicline prescribing was higher amongst smokers without neurodevelopmental 
disorders which may be indicative of increased cautiousness by physicians to prescribe varenicline to people with 
neurodevelopmental disorders. The latter could be related to the safety warnings that were raised about vareni-
cline by the MHRA in the UK18. However, it is worth noting that these warnings have been dropped since 2016 
based on the results from the EAGLES clinical trial21. The steady decline in NRT prescriptions and the eventual 
decline in varenicline prescriptions after 2011 may be partially attributed to the rise in e-cigarette popularity32, to 
the availability of over-the-counter smoking cessation medications, or indicate a decline in provision of smoking 
cessation services.
Our safety analysis of varenicline use for smoking cessation in patients with neurodevelopmental disorders 
as compared to NRT revealed little evidence of increased likelihood of adverse events such as self-harm, depres-
sion, anxiety and prescriptions of antidepressants and hypnotics/anxiolytics. These results were consistent with 
evidence from observational20,33 and clinical studies16,21,22. These mounting and consistent findings that find little 
evidence that varenicline has few detectable mental health side effects compared to NRT should provide reassur-
ance to clinicians.
People with neurodevelopmental disorders should have access to the most effective smoking cessation treat-
ments to reduce the burden of smoking-related health inequalities in this group. Although the NHS introduced a 
Directed Enhanced Service (DES) in 200934 to provide annual health checks for people with learning disabilities 
(those were the largest group in our cohort of people with neurodevelopmental disorders) and ultimately improve 
their health, this has not translated to better smoking cessation advocacy in the primary care setting. Our results 
Fully adjusted odds ratio (95% confidence interval)†
3-months 6-months 9-months 1-year 2-years 4-years
No neurodevelopmental 
disorder (N = 232,968) 1.42 (1.38 to 1.47) 1.45 (1.41 to 1.50) 1.39 (1.36 to 1.43) 1.33 (1.30 to 1.37) 1.25 (1.22 to 1.27) 1.17 (1.14 to 1.19)
Any neurodevelopmental 
disorder (N = 2,344) 1.45 (1.03 to 2.05) 1.63 (1.23 to 2.17) 1.61 (1.23 to 2.12) 1.31 (0.99 to 1.73) 1.38 (1.06 to 1.78) 1.32 (1.02 to 1.71)
Autism (N = 258) 5.13 (1.24 to 21.25) 9.27 (1.91 to 45.01) 5.87 (1.70 to 20.27) 4.87 (1.52 to 15.60) 3.16 (1.09 to 9.20) 1.96 (0.74 to 5.19)
ADHD (N = 524) 1.40 (0.63 to 3.13) 1.50 (0.74 to 3.03) 1.81 (0.99 to 3.33) 0.91 (0.50 to 1.66) 1.08 (0.62 to 1.91) 1.13 (0.66 to 1.95)
Intellectual disability 
(N = 1,720) 1.39 (0.92 to 2.12) 1.62 (1.16 to 2.27) 1.55 (1.11 to 2.15) 1.43 (1.03 to 1.97) 1.40 (1.03 to 1.91) 1.33 (0.97 to 1.83)
Table 2. Stratified by mental disorder: Fully adjusted odds ratios and 95% confidence intervals for the 
association between prescription of varenicline versus NRT and smoking cessation at 3, 6 and 9-months and 
1, 2, and 4-years after prescription. †Fully adjusted models were adjusted for: age, sex, days in history, IMD, 
number of GP visits 1-year prior to first prescription, BMI, year of first prescription, history of major physical 
morbidity (Charlson Index), alcohol misuse ever, drug misuse ever, depression ever, neurotic disorder ever, 
schizophrenia ever, self-harm ever, antidepressant prescription ever, antipsychotic prescription ever, hypnotics/
anxiolytics prescription ever, other psychotropic medication ever, and other behavioral/neurologic disorder 
ever. Missing BMI and IMD values were imputed using multiple imputation.
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signal that such efforts should be refined to tackle the high prevalence of smoking and low rate of prescribing 
varenicline for smoking cessation in patients with neurodevelopmental disorders.
We found that smoking prevalence was higher in people with neurodevelopmental disorders (with the excep-
tion of ASD) as compared to those without these disorders. Varenicline was less likely to be prescribed to patients 
with neurodevelopmental disorders although our data suggests that it is more effective than NRT in achieving 
smoking abstinence in this patient group. We found little evidence that varenicline produced higher adverse 
events in terms of suicidal behaviour, depression, and anxiety than NRT in patients with neurodevelopmental dis-
orders. This evidence may be useful in refining clinical guidelines on the use of varenicline for smoking cessation 
and reducing health inequalities in people with neurodevelopmental disorders.
Methods
Study design and data source. We conducted a prospective cohort study using the UK Clinical Practice 
Research Datalink (CPRD). The CPRD comprises anonymised data from over 13 million primary care patients 
gathered by 683 general practices (GPs) across the UK since 1987. Data include, but are not limited to: demo-
graphics, laboratory tests, imaging, diagnoses, therapies, hospital referrals and health-related behaviours35. The 
CPRD is broadly representative of the UK general population regarding key demographics such as age, sex, and 
ethnicity35. To ensure the integrity of the data, the CPRD data are validated, audited and quality checked36.
Study population. We included people with Read codes indicating one of the following neurodevelop-
mental disorders (these were considered life-long conditions) at any time in the CPRD: (1) ASD (F84.0–84.1, 
F84.4–84.9), (2) intellectual disability (F70–79), and (3) ADHD (F90) and/or prescription of central nervous 
system stimulants (BNF chapter 4.4). There are no other licensed or off-licence indications for stimulant use other 
than ADHD. It is therefore common for epidemiological studies to use ADHD medications as a proxy for ADHD 
diagnoses37. People without the above Read codes were considered to have no neurodevelopmental disorder. Only 
people whose records originated from GPs that were up to standard and were deemed acceptable by the CPRD 
were included in the analysis (i.e., the included population had no gaps in their electronic medical records and 
had no missing key information such as year of birth, registration date or sex).
Code lists. We extracted the variables for this study using medical and product codes within the CPRD. For 
a subset of the data, we used linked Office for National Statistics (ONS) mortality data to extract codes related 
to deaths by suicide. Where available, previously published lists were used27. Otherwise, code lists were created 
by consulting with field experts (RMM, DR, KHT) and by using the British National Formulary (BNF) and the 
International Classification of Diseases (ICD-10).
Smoking status. We extracted smoking records from clinical files and additional data tables using Read codes 
specific to smoking, in addition to codes indicating prescription of smoking cessation medication extracted from 
therapy data files. Those were captured using prescribed medicines in BNF category 4.10.2 (Nicotine Dependence). 
According to the recent Quality and Outcomes Framework (QOF) guidelines (these are quality standards against 
which the priority areas for quality improvement in health and social care are set out), smoking status (non-smoker, 
current smoker, or ex-smoker) should be recorded by GPs annually for smokers, annually for ex-smokers for three 
consecutive years, and annually for non-smokers until they reach the age of 2536. These smoking records provide 
data that are consistent with smoking prevalence reported in representative population surveys38.
Effectiveness and safety of varenicline vs NRT. Exposure measures. Individuals aged 18 years and 
older prescribed varenicline from 1st September 2006 were compared to users of NRT (i.e., nicotine patches, gum, 
lozenges, mini-tabs and inhalers, defined using medicines in British National Formulary (BNF) category 4.10.2 
as described above). Only first-time users of smoking cessation medications were included. First-time use of the 
smoking cessation therapies was defined as having no prior record of use of a related product in the preceding 
18-months. We did not model treatment switching, as this is strongly related to patient characteristics. To ensure 
comprehensive assessment of baseline data and possible confounders, people who registered with the GP practice 
within 365 days of their first recorded smoking medication were excluded. We also excluded people who were 
initially prescribed NRT and varenicline simultaneously and those who were prescribed bupropion in the year 
before their first prescription of varenicline or NRT.
Outcome measures. The pre-specified primary outcome was smoking cessation at 2-years follow-up39. Smoking 
cessation was also assessed at 3, 6, and 9-months, and at 1 and 4-years after first prescription. Smoking status was 
ascertained by using each person’s most recent smoking record identified between cohort entry and each follow-up 
period (e.g., 3-months, 6-months, 1-year). The closest smoking record to each follow-up period was selected.
Safety-related outcomes were incident self-harm, depression, anxiety, and prescription of antidepressants and 
hypnotics/anxiolytics (see Supplementary Appendix), assessed at 3, 6, and 9-months, and at 1, 2 and 4-years after 
the index prescription of smoking cessation medications
Covariates. Covariates defined at the time of prescription included age, sex, index of multiple deprivation 
(IMD) that reflects the individual’s socioeconomic position, number of GP visits 1-year prior to first prescription, 
body mass index (BMI), year of first prescription, days registered in the CPRD, Charlson Index that is a measure 
of comorbidity, ever alcohol misuse, ever drug misuse, ever self-harm, history of mental health disorder (anxiety 
and stress related disorders, depression, bipolar disorder, schizophrenia and non-affective psychoses, eating and 
personality disorders), and history of psychotropic medication prescriptions (antidepressants, antipsychotics, 
hypnotics/anxiolytics, or mood stabilisers).
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Statistical analysis. Smoking prevalence. To estimate the prevalence of smoking in the target popula-
tion, we divided the number of people with neurodevelopmental disorders aged 18 years and over who had 
Read codes indicating current smoking for each year between 2004 and 2015 by the total number of people 
with a smoking status code (indicating current or non/ex-smoking) each year between 2004 and 2015 (eTa-
ble 1). For comparison, smoking prevalence was also estimated amongst individuals without neurodevelop-
mental disorders.
Prescribing prevalence. The prevalence of varenicline and NRT prescribing amongst current smokers was cal-
culated by dividing the number of prescriptions each year from 2007 to 2015 (there were no varenicline prescrip-
tions for patients with neurodevelopmental disorders in 2006) by the number of current smokers in each year. 
Prevalence was estimated for people with and without neurodevelopmental disorders.
Smoking and prescribing prevalence rates were directly age- and sex- standardised to account for differences 
in age and sex between groups with and without neurodevelopmental disorders. We used the CPRD population 
in 2015 as our standard population for calculating standardised smoking rates, and the CPRD smoker population 
in 2015 as our standard population for calculating standardised prescribing prevalence rates. Age was grouped 
into five categories (18–24, 25–34, 35–49, 50–59, 60+ years).
Varenicline effectiveness and safety. The effectiveness and safety of varenicline versus NRT on smoking cessa-
tion was determined using three statistical approaches to try to overcome confounding. Firstly, we fitted mul-
tivariable logistic regression models adjusting for all covariates and using robust standard errors to account 
for potential clustering within practices. These analyses were conducted in the following patient groups: no 
neurodevelopmental disorder, any neurodevelopmental disorder, ASD, ADHD, and intellectual disabilities. 
Secondly, we repeated the analyses using propensity score matched logistic regression. Developing the propen-
sity score model involved fitting a logistic regression model including all baseline covariates to calculate each 
participant’s propensity score. Then, within each neurodevelopmental disorder group, each person prescribed 
varenicline was matched to another person prescribed NRT with the closest propensity score in a ratio of 1:1 
using a nearest neighbour algorithm with no replacement, and matching was restricted to the common support 
region40. Those who could not be matched were discarded from that analysis. Thirdly, we utilized instrumental 
variable regression analyses, with physicians’ previously recorded prescribing preferences for varenicline versus 
NRT as the instrument. The instrument (physicians’ prescribing preference) was defined by the seven smoking 
cessation prescriptions previously issued by the physician to their previous patients before their current patient. 
Physicians who previously prescribed varenicline were categorised as a varenicline prescriber41. The instrumen-
tal variable regression models were developed in two groups (patients with and without neurodevelopmental 
disorders) due to insufficient power to display meaningful results by individual neurodevelopmental disorders. 
Instrumental variable assumptions for our study were: (1) the physicians’ prescribing preference was associated 
with the probability they will prescribe varenicline rather than NRT to their patient; (2) the physicians’ prescrib-
ing preference for varenicline or NRT does not affect smoking cessation other than through the decision on 
whether to prescribe varenicline or NRT; and (3) the physicians’ prescribing preference for varenicline or NRT 
is not related to characteristics of their patient population. The instrument used in this study was previously 
reported as a potential approach to control for confounding by indication in nonexperimental studies16,20,41,42. 
All analyses were conducted using Stata 14 MP.
Missing data. Patients with missing smoking data during the follow-up period (beyond 180 days) were 
assumed to be continuing smokers43. This has been shown to be robust to sensitivity analyses16. We used mul-
tiple imputation to handle missing data on BMI and IMD. This was done using the ICE command in Stata 
where we produced 20 imputed datasets (eTable 2). We included all exposures, covariates, and outcomes in the 
imputation model26.
Ethical considerations. The study was approved by the Independent Scientific Advisory Committee (ISAC) 
on 04/06/2015 (protocol number 15_115). Patient and practice confidentiality was maintained in accordance with 
the CPRD policy on personal data (https://www.cprd.com/dataAccess/).
Data statement. This study is based in part on data from the Clinical Practice Research Datalink obtained 
under licence from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by 
patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained 
in this study are those of the authors alone.
Data access. The data can be accessed by submitting an application to ISAC: https://cprd.com/Data-access. 
Codelists that were used for this study are available upon request from the corresponding author.
Received: 4 October 2018; Accepted: 5 November 2019;
Published: xx xx xxxx
References
 1. Thapar, A., Cooper, M. & Rutter, M. Neurodevelopmental disorders. Lancet Psychiatry. 4, 339–346 (2017).
 2. Glassgow, A. E. & Van Voorhees, B. Behavioral Health Disparities Among Children and Youth with Special Health Care Needs. 
Pediatr Ann. 46, e382–e386 (2017).
 3. Raouafi, S., Achiche, S. & Raison, M. Socioeconomic disparities and difficulties to access to healthcare services among Canadian 
children with neurodevelopmental disorders and disabilities. Epidemiol Health. 40, e2018010 (2018).
8Scientific RepoRtS |         (2019) 9:19488  | https://doi.org/10.1038/s41598-019-54727-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 4. Emerson, E., Hatton, C., Baines, S. & Robertson, J. The physical health of British adults with intellectual disability: cross sectional 
study. Int J Equity Health. 15, 11 (2016).
 5. Allerton, L. & Emerson, E. British adults with chronic health conditions or impairments face significant barriers to accessing health 
services. Public Health. 126, 920–927 (2012).
 6. Lambert, N. M. & Hartsough, C. S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD 
and non-ADHD participants. J Learn Disabil. 31, 533–544 (1998).
 7. Milberger, S., Biederman, J., Faraone, S. V., Chen, L. & Jones, J. ADHD is associated with early initiation of cigarette smoking in 
children and adolescents. J Am Acad Child Adolesc Psychiatry. 36, 37–44 (1997).
 8. Pomerleau, O. F., Downey, K. K., Stelson, F. W. & Pomerleau, C. S. Cigarette smoking in adult patients diagnosed with attention 
deficit hyperactivity disorder. J Subst Abuse. 7, 373–378 (1995).
 9. Tracy, J. & Hosken, R. The importance of smoking education and preventative health strategies for people with intellectual disability. 
J Intellect Disabil Res. 41, 416–421 (1997).
 10. Bejerot, S. & Nylander, L. Low prevalence of smoking in patients with autism spectrum disorders. Psychiatry Res. 119, 177–182 
(2003).
 11. Statistics Sweden. Consumption of tobacco in Sweden 2001 [Available from: http://www.scb.se/ (2001).
 12. Robertson, J. et al. Lifestyle related risk factors for poor health in residential settings for people with intellectual disabilities. Res Dev 
Disabil. 21, 469–486 (2000).
 13. Taylor., N. S., Standen, P. J., Cutajar, P., Fox, D. & Wilson, D. N. Smoking prevalence and knowledge of associated risks in adult 
attenders at day centres for people with learning disabilities. J Intellect Disabil Res. 48, 239–244 (2004).
 14. Aubin, H. J. et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. 
Thorax. 63, 717–724 (2008).
 15. Gonzales, D. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and 
placebo for smoking cessation: a randomized controlled trial. JAMA. 296, 47–55 (2006).
 16. Taylor, G. M. J. et al. The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary 
care: a prospective cohort study of electronic medical records. Int J Epidemiol. 46, 1948–1957 (2017).
 17. Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T. & Gunnell, D. Risk of neuropsychiatric adverse events associated with 
varenicline: systematic review and meta-analysis. BMJ. 350, https://doi.org/10.1136/bmj.h1109 (2015).
 18. Medicines and Healthcare Products Regulatory Agency (MHRA). Varenicline: adverse psychiatric reactions, including depression: 
Drug Safety Update (2008).
 19. United States Food and Drug Adminstration (USFDA). FDA Drug Safety Communication: FDA revises description of mental health 
side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (2016).
 20. Thomas, K. H. et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research 
Datalink: prospective cohort study. BMJ. 347, f5704 (2013).
 21. Anthenelli, R. M. et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and 
without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 387, 2507–2520 
(2016).
 22. Evins, A. E. et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, 
anxiety, and mood disorders in the EAGLES trial. J Clin Psychopharmacol. 39, 108–116 (2019).
 23. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. Int J Epidemiol. 45, 1866–1886 (2016).
 24. McMahon, A. D. Approaches to combat with confounding by indication in observational studies of intended drug effects. 
Pharmacoepidemiol Drug Saf. 12, 551–558 (2003).
 25. Herrett, E. et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 44, 827–836 (2015).
 26. Sterne, J. A. C. et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 338, 
https://doi.org/10.1136/bmj.b2393 (2009).
 27. Emerson, E. Health status and health risks of the “hidden majority” of adults with intellectual disability. Intellect Dev Disabil. 49, 
155–165 (2011).
 28. Szatkowski, L. & McNeill, A. The delivery of smoking cessation interventions to primary care patients with mental health problems. 
Addiction. 108, 1487–1494 (2013).
 29. Szatkowski, L. & McNeill, A. Diverging trends in smoking behaviors according to mental health status. Nicotine Tob Res. 17, 356–360 
(2015).
 30. Office for National Statistics. Adult Smoking Habits in the UK: 2016 [Available from: https://www.ons.gov.uk/
peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2016 
(2016).
 31. UK Centre for Tobacco and Alcohol Studies. Prescribing of smoking cessation medication in England 2009 [Available from: http://
www.ukctas.ac.uk/documents/thin-prescribing.pdf (2009).
 32. Office for National Statistics. E-Cigarette Use in Great Britain 2017 (2017).
 33. Gunnell, D., Irvine, D., Wise, L., Davies, C. & Martin, R. M. Varenicline and suicidal behaviour: a cohort study based on data from 
the General Practice Research Database. BMJ. 339, https://doi.org/10.1136/bmj.b3805 (2009).
 34. National Health Service England. Learning disabilities health check scheme, England, Quarters 1 and 2, 2016-17 2017 [Available 
from: https://digital.nhs.uk/catalogue/PUB23804 (2017).
 35. Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L. & Hall, A. J. Validation and validity of diagnoses in the General Practice 
Research Database: a systematic review. Br J Clin Pharmacol. 69, 4–14 (2010).
 36. National Health Service England. 2016/17 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF) 
2016 [Available from: http://www.nhsemployers.org/~/media/Employers/Documents/Primary%20care%20contracts/QOF/2016-
17/2016-17%20QOF%20guidance%20documents.pdf (2016).
 37. Larsson, H. et al. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J 
Psychiatry. 203, 103–106 (2013).
 38. Booth, H. P., Prevost, A. T. & Gulliford, M. C. Validity of smoking prevalence estimates from primary care electronic health records 
compared with national population survey data for England, 2007 to 2011. Pharmacoepidemiol Drug Saf. 22, 1357–1361 (2013).
 39. Davies, N. M. et al. What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation 
and clinically important outcomes? Protocol for a prospective cohort study. BMJ Open. 5, e009665 (2015).
 40. Rosenbaum, P. R. & Rubin, D. B. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate 
the Propensity Score. The American Statistician. 39, 33–38 (1985).
 41. Davies, N. M. et al. Physicians’ prescribing preferences were a potential instrument for patients’ actual prescriptions of 
antidepressants. J Clin Epidemiol. 66, 1386–1396 (2013).
 42. Brookhart, M. A., Wang, P. S., Solomon, D. H. & Schneeweiss, S. Evaluating short-term drug effects using a physician-specific 
prescribing preference as an instrumental variable. Epidemiology. 17, 268–275 (2006).
 43. West, R., Hajek, P., Stead, L. & Stapleton, J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 
100, 299–303 (2005).
9Scientific RepoRtS |         (2019) 9:19488  | https://doi.org/10.1038/s41598-019-54727-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
This research was supported by Global Research Awards for Nicotine Dependence (GRAND), an independently 
reviewed competitive grants program supported by Pfizer, to the University of Bristol. The funder had no role 
in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Medical 
Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_
UU_12013/1 MC_UU_12013/6 MC_UU_12013/9, MC_UU_00011/1 MC_UU_00011/7]. The research described 
in this paper was funded by the Medical Research Council methodology grant [MR/N01006X/1]. KHT is funded 
by a National Institute for Health Research (NIHR) Postdoctoral Fellowship- PDF-2017-10-068 for this research 
project. TJ’s time is supported by the National Institute for Health Research Applied Research Collaboration West 
(NIHR ARC West) at University Hospitals Bristol NHS Foundation Trust. R.M.M. is supported by the NIHR 
Bristol Biomedical Research Centre, a partnership between the University Hospitals Bristol NHS Foundation 
Trust and the University of Bristol; and by a Cancer Research UK Programme Grant (C18281/A19169). GMJT 
is funded by a Cancer Research UK Postdoctoral Fellowship (C56067/A21330). This study was supported by the 
NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University 
of Bristol. This publication presents independent research funded by the National Institute for Health Research 
(NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, 
the National Institute for Health Research or the Department of Health and Social Care.
Author contributions
T.I. contributed to data cleaning, data analysis, interpretation of results and writing the manuscript. G.T., N.D., 
A.T. and K.T. contributed to study conceptualization, study design, interpretation of results, data analysis 
and writing the manuscript. R.M.M., M.M. and D.R. contributed to study conceptualization, study design, 
interpretation of results and writing the manuscript. T.J. extracted the data and contributed to writing the 
manuscript. T.I., A.T. and N.D. had full access to all of the data in the study and takes responsibility for the 
integrity of the data and the accuracy of the data analysis.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-54727-5.
Correspondence and requests for materials should be addressed to A.E.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
